Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

PubWeight™: 4.39‹?› | Rank: Top 1%

🔗 View Article (PMC 3936420)

Published in Cancer Discov on November 21, 2013

Authors

Hubing Shi1,2, Willy Hugo1,2, Xiangju Kong1,2, Aayoung Hong1,3,2, Richard C Koya4,2, Gatien Moriceau1,2, Thinle Chodon5,2, Rongqing Guo5,2, Douglas B Johnson6,7, Kimberly B Dahlman8,7, Mark C Kelley9,7, Richard F Kefford10, Bartosz Chmielowski5,11,2, John A Glaspy5,11,2, Jeffrey A Sosman6,7, Nicolas van Baren12, Georgina V Long10, Antoni Ribas1,5,11,3,2, Roger S Lo1,11,3,2

Author Affiliations

1: Division of Dermatology, Department of Medicine.
2: David Geffen School of Medicine, University of California, LA, California 90095-1662 USA.
3: Department of Molecular and Medical Pharmacology.
4: Division of Surgical Oncology, Department of Surgery.
5: Division of Hematology & Oncology, Department of Medicine.
6: Department of Medicine.
7: Vanderbilt-Ingram Cancer Center, Nashville, TN 37232.
8: Department of Cancer Biology.
9: Department of Surgery.
10: Melanoma Institute of Australia, Westmead Millenium Institute, Westmead Hospital, University of Sydney, New South Wales, Australia.
11: Jonsson Comprehensive Cancer Center.
12: Ludwig Institute for Cancer Research, Brussels Branch, Belgium.

Articles citing this

(truncated to the top 100)

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 4.29

Therapy-induced tumour secretomes promote resistance and tumour progression. Nature (2015) 3.07

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell (2015) 2.94

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature (2014) 2.84

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell (2016) 2.39

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell (2015) 2.12

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun (2014) 2.10

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell (2015) 1.91

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75

Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res (2014) 1.70

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci U S A (2015) 1.67

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64

PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov (2014) 1.58

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol (2014) 1.55

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol (2014) 1.47

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 1.33

Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26

Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther (2014) 1.18

Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (2015) 1.12

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest (2015) 1.11

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med (2015) 1.11

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res (2015) 1.09

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res (2014) 1.08

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer (2015) 1.07

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov (2014) 1.02

Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics (2014) 1.00

BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res (2014) 0.99

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer (2015) 0.99

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther (2015) 0.99

Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. Mol Syst Biol (2015) 0.98

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov (2016) 0.98

Big data: the next frontier for innovation in therapeutics and healthcare. Expert Rev Clin Pharmacol (2014) 0.97

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer (2014) 0.96

Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One (2014) 0.96

Towards a unified model of RAF inhibitor resistance. Cancer Discov (2014) 0.95

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med (2014) 0.95

BRAF Mutation in Colorectal Cancer: An Update. Biomark Cancer (2015) 0.95

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. J Clin Oncol (2016) 0.94

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A (2015) 0.93

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest (2016) 0.93

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91

Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med (2016) 0.90

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat Commun (2014) 0.90

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun (2015) 0.90

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. Trends Cancer (2016) 0.90

Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Front Oncol (2015) 0.88

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med (2015) 0.87

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res (2014) 0.87

Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma. J Cancer (2015) 0.87

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol (2016) 0.87

Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.87

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. Br J Cancer (2016) 0.86

Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun (2016) 0.85

Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res (2014) 0.85

Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85

Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report. BMC Clin Pathol (2015) 0.85

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One (2015) 0.84

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget (2015) 0.84

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Mol Cancer Ther (2015) 0.83

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. Oncotarget (2015) 0.83

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front Cell Dev Biol (2016) 0.83

miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget (2016) 0.83

Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol (2016) 0.82

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82

Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget (2015) 0.81

Advancing clinical oncology through genome biology and technology. Genome Biol (2014) 0.81

Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag (2016) 0.81

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res (2016) 0.80

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet. Front Oncol (2015) 0.80

Future Perspective of Single-Molecule FRET Biosensors and Intravital FRET Microscopy. Biophys J (2016) 0.80

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget (2016) 0.80

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res (2015) 0.80

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80

EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther (2016) 0.79

Novel melanoma therapy. Exp Hematol Oncol (2016) 0.79

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am J Cancer Res (2015) 0.79

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget (2016) 0.79

Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Exp Dermatol (2015) 0.79

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget (2016) 0.78

PIM kinases as therapeutic targets against advanced melanoma. Oncotarget (2016) 0.78

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget (2016) 0.78

Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78

miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci U S A (2016) 0.78

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. EBioMedicine (2016) 0.78

Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol (2014) 0.78

ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Rep (2017) 0.78

MicroRNAs in melanoma development and resistance to target therapy. Oncotarget (2017) 0.78

Approaches to modernize the combination drug development paradigm. Genome Med (2016) 0.77

Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol (2015) 0.77

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget (2016) 0.77

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl Med (2015) 0.77

Articles cited by this

The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51

A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics (2005) 34.83

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

I-TASSER server for protein 3D structure prediction. BMC Bioinformatics (2008) 18.28

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res (2009) 12.58

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42

Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science (1998) 6.79

Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59

Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics (2011) 5.45

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78

Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature (2012) 3.92

A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A (2009) 2.85

The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27

Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J (2003) 2.15

The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle (2012) 1.98

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86

Cytosine methylation and DNA repair. Curr Top Microbiol Immunol (2006) 1.82

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75

Crystal structure of the phosphatidylinositol 3,4-bisphosphate-binding pleckstrin homology (PH) domain of tandem PH-domain-containing protein 1 (TAPP1): molecular basis of lipid specificity. Biochem J (2001) 1.27

Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J (2012) 1.23

Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl (2013) 1.21

Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California. Pigment Cell Melanoma Res (2013) 0.95